Twist Bioscience Corp: Form 10-Q for the period ended Mar 31, 2024
Filed with the SEC on May 2, 2024 and accepted by EDGAR at May 2, 2024, 16:13 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-01-01 to 2024-03-31 | $75.3m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months2023-10-01 to 2024-03-31 | $146.8m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2024-01-01 to 2024-03-31 | $44.4m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2023-10-01 to 2024-03-31 | $87.0m | us-gaap:CostOfRevenue |
| Research and development | 3 months2024-01-01 to 2024-03-31 | $24.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-10-01 to 2024-03-31 | $47.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-01-01 to 2024-03-31 | $55.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-10-01 to 2024-03-31 | $108.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-01-01 to 2024-03-31 | −$48.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-10-01 to 2024-03-31 | −$95.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-01-01 to 2024-03-31 | $0 | us-gaap:InterestExpense |
| Interest expense | 6 months2023-10-01 to 2024-03-31 | $0 | us-gaap:InterestExpense |
| Income tax | 3 months2024-01-01 to 2024-03-31 | $345.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-10-01 to 2024-03-31 | $465.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-01-01 to 2024-03-31 | −$45.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-10-01 to 2024-03-31 | −$88.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-01-01 to 2024-03-31 | −$0.79 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-10-01 to 2024-03-31 | −$1.54 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-01-01 to 2024-03-31 | −$0.79 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-10-01 to 2024-03-31 | −$1.54 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-01-01 to 2024-03-31 | 57,779,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-10-01 to 2024-03-31 | 57,637,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-10-01 to 2024-03-31 | −$42.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-10-01 to 2024-03-31 | $2.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-03-31 | $243.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $371.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $702.8m | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $67.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-03-31 | $142.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-03-31 | $560.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-24-020014. Last ingested by Listed: Oct 27, 2026, 16:07 ET. Listed shows no prices and gives no investment advice.